 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123 |
- | Leqselvi (deuruxolitinib) / Sun Pharma
New P1 trial: Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers (clinicaltrials.gov) - Sep 16, 2019
P1, N=6, Active, not recruiting, Sponsor: Concert Pharmaceuticals
- | Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion: Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - Sep 4, 2019
P2, N=149, Completed, Sponsor: Concert Pharmaceuticals
Active, not recruiting --> Completed
- || Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion: Food Effect Study of CTP-543 in Healthy Volunteers (clinicaltrials.gov) - Jun 12, 2019
P1, N=14, Completed, Sponsor: Concert Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Leqselvi (deuruxolitinib) / Sun Pharma
Enrollment closed: Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - Jun 5, 2019
P2, N=57, Active, not recruiting, Sponsor: Concert Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Leqselvi (deuruxolitinib) / Sun Pharma
Enrollment open: Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - May 19, 2019
P2, N=60, Recruiting, Sponsor: Concert Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Leqselvi (deuruxolitinib) / Sun Pharma
New P2 trial: Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - May 7, 2019
P2, N=60, Not yet recruiting, Sponsor: Concert Pharmaceuticals
- |||| Leqselvi (deuruxolitinib) / Sun Pharma
New P2 trial: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - Apr 2, 2019
P2, N=100, Recruiting, Sponsor: Concert Pharmaceuticals
- || Leqselvi (deuruxolitinib) / Sun Pharma
Enrollment closed: Food Effect Study of CTP-543 in Healthy Volunteers (clinicaltrials.gov) - Apr 1, 2019
P1, N=14, Active, not recruiting, Sponsor: Concert Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- || Leqselvi (deuruxolitinib) / Sun Pharma
New P1 trial: Food Effect Study of CTP-543 in Healthy Volunteers (clinicaltrials.gov) - Mar 19, 2019
P1, N=14, Not yet recruiting, Sponsor: Concert Pharmaceuticals
- ||| Leqselvi (deuruxolitinib) / Sun Pharma
Enrollment open: Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - Mar 7, 2019
P2, N=60, Recruiting, Sponsor: Concert Pharmaceuticals
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Leqselvi (deuruxolitinib) / Sun Pharma
Enrollment closed: Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - Jan 23, 2019
P2, N=149, Active, not recruiting, Sponsor: Concert Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Leqselvi (deuruxolitinib) / Sun Pharma
New P2 trial: Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - Jan 21, 2019
P2, N=60, Not yet recruiting, Sponsor: Concert Pharmaceuticals
- | Leqselvi (deuruxolitinib) / Sun Pharma
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - Sep 27, 2018
P2, N=125, Recruiting, Sponsor: Concert Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | N=90 --> 125 | Trial completion date: Dec 2018 --> Aug 2019 | Trial primary completion date: Dec 2018 --> Jul 2019
- ||||| Leqselvi (deuruxolitinib) / Sun Pharma
New P2 trial: Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - Dec 19, 2017
P2, N=90, Recruiting, Sponsor: Concert Pharmaceuticals
- |||| Leqselvi (deuruxolitinib) / Sun Pharma
Enrollment open: Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - Jul 31, 2017
P2, N=90, Recruiting, Sponsor: Concert Pharmaceuticals
Active, not recruiting --> Recruiting | N=90 --> 125 | Trial completion date: Dec 2018 --> Aug 2019 | Trial primary completion date: Dec 2018 --> Jul 2019 Not yet recruiting --> Recruiting
- ||| ruxolitinib deuterated (CTP-543) / Concert Pharma
Clinical: Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - Jul 13, 2017
P2, N=90, Not yet recruiting, Sponsor: Concert Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: May 2017 --> Aug 2017 | Trial primary completion date: Mar 2018 --> Dec 2018
- | ruxolitinib deuterated (CTP-543) / Concert Pharma
Clinical: Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - May 29, 2017
P2, N=100, Suspended, Sponsor: Concert Pharmaceuticals
Initiation date: May 2017 --> Aug 2017 | Trial primary completion date: Mar 2018 --> Dec 2018 Recruiting --> Suspended
- ||||| ruxolitinib deuterated (CTP-543) / Concert Pharma
Clinical: Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - May 1, 2017
P2, N=100, Recruiting, Sponsor: Concert Pharmaceuticals
- | Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion: Open-Label Crossover Study Comparing CTP-543 to Jakafi (clinicaltrials.gov) - Mar 28, 2017
P1, N=12, Completed, Sponsor: Concert Pharmaceuticals
Recruiting --> Suspended Recruiting --> Completed
- ||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion: Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects (clinicaltrials.gov) - Mar 13, 2017
P1, N=77, Completed, Sponsor: Concert Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- || Leqselvi (deuruxolitinib) / Sun Pharma
Enrollment closed: Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects (clinicaltrials.gov) - Dec 15, 2016
P1, N=77, Active, not recruiting, Sponsor: Concert Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Leqselvi (deuruxolitinib) / Sun Pharma
New P1 trial: Open-Label Crossover Study Comparing CTP-543 to Jakafi (clinicaltrials.gov) - Nov 9, 2016
P1, N=12, Recruiting, Sponsor: Concert Pharmaceuticals
- ||| Leqselvi (deuruxolitinib) / Sun Pharma
Enrollment open: Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects (clinicaltrials.gov) - Jun 17, 2016
P1, N=82, Recruiting, Sponsor: Concert Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Leqselvi (deuruxolitinib) / Sun Pharma
New P1 trial: Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects (clinicaltrials.gov) - May 19, 2016
P1, N=82, Not yet recruiting, Sponsor: Concert Pharmaceuticals